Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart inhaler app aims to help asthma patients breathe easier

NCT ID NCT03890666

Disease control Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a digital system that includes a smart inhaler, a phone app, and a dashboard for doctors to help people with asthma better manage their condition. Over 12 weeks, 333 participants aged 13 and older used either the smart system or their usual rescue inhaler. The goal was to see if the smart system could improve asthma control, as measured by a simple questionnaire.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
albuterol sulfate (rescue inhaler)
What this could lead to
If successful, this smart inhaler system could help people with asthma better track and manage their symptoms, leading to improved asthma control.
What could go wrong
This is a small, short-term feasibility study, so results may not apply to everyone. The smart system may not work for all users or lead to lasting improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

333 people

The number who actually took part.

Started

Oct 2020

Finished

Oct 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participant has a documented diagnosis of asthma * The participant is currently on treatment with an inhaled corticosteroid (ICS) with a long-acting beta2 antagonist (LABA). * The participant is currently using inhaled albuterol sulfate as rescue medication and is willing to discontinue all other rescue medications and replace them with the study provided Albuterol eMDPI. * The participant can read and communicate in English and is familiar with and is willing to use his/her own smart device and download and use the App. * Additional criteria apply, please contact the investigator for more information Exclusion Criteria: * The participant has any clinically significant uncontrolled medical condition (treated or untreated) other than asthma. * The participant was hospitalized for severe asthma in the last 30 days. * The participant has a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap (ACO). * The participant is a current smoker or has a greater than 10 pack-year history of smoking. * The participant is currently being treated with systemic corticosteroids (oral, intramuscular, or intravenous) or has been treated within the last 30 days. * The participant has any treatment with biologics for asthma (for example, omalizumab, anti-IL5, anti-IL5R, anti-IL4R), or has had such treatment within the last 90 days. * Additional criteria apply, please contact the investigator for more information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Teva Investigational Site 14187

    Cincinnati, Ohio, 45231, United States

  • Teva Investigational Site 14188

    San Antonio, Texas, 78207, United States

  • Teva Investigational Site 14189

    San Antonio, Texas, 78251, United States

  • Teva Investigational Site 14190

    Greenfield, Wisconsin, 53228, United States

  • Teva Investigational Site 14191

    Owensboro, Kentucky, 42301, United States

  • Teva Investigational Site 14192

    San Antonio, Texas, 78229, United States

  • Teva Investigational Site 14195

    Savannah, Georgia, 31406, United States

  • Teva Investigational Site 14196

    Greenville, South Carolina, 29607, United States

  • Teva Investigational Site 14197

    Aventura, Florida, 33180, United States

  • Teva Investigational Site 14198

    Denver, Colorado, 80206, United States

  • Teva Investigational Site 14200

    Providence, Rhode Island, 02906, United States

  • Teva Investigational Site 14207

    Bellevue, Nebraska, 68123-4303, United States

  • Teva Investigational Site 14208

    Pittsburgh, Pennsylvania, 15241, United States

  • Teva Investigational Site 14210

    Philadelphia, Pennsylvania, 19140, United States

  • Teva Investigational Site 14215

    Sarasota, Florida, 34239, United States

  • Teva Investigational Site 14217

    Evanston, Illinois, 60201, United States

  • Teva Investigational Site 14218

    Springfield, Illinois, 62704, United States

  • Teva Investigational Site 14220

    New Haven, Connecticut, 06510, United States

  • Teva Investigational Site 14221

    New York, New York, 10461, United States

  • Teva Investigational Site 14232

    Birmingham, Alabama, 35209, United States

  • Teva Investigational Site 14233

    Ann Arbor, Michigan, 48109, United States

  • Teva Investigational Site 14234

    Chapel Hill, North Carolina, 27599, United States

  • Teva Investigational Site 14236

    Colorado Springs, Colorado, 80907, United States

  • Teva Investigational Site 14300

    Charleston, South Carolina, 29407, United States

  • Teva Investigational Site 14301

    Stockton, California, 95207-6204, United States

  • Teva Investigational Site 14302

    Los Angeles, California, 90025, United States

  • Teva Investigational Site 14304

    Albany, Georgia, 31707, United States

  • Teva Investigational Site 14305

    Louisville, Kentucky, 40215, United States

  • Teva Investigational Site 14306

    Miami, Florida, 33186, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.